Key highlights
- Achieved 27% clinical remission rate at the 20 mg BID dose compared to 20% at 10 mg BID
- Met primary endpoint with a mean reduction of 2.4 points in the modified Mayo score at Week 12
- Reported 61% clinical response and 49% symptomatic remission in the pooled 20 mg BID group
- Observed rapid onset of benefit with 21% symptomatic remission achieved by Week 2
- Confirmed favorable tolerability profile with no new safety signals during the induction period
What Happened
Odyssey Therapeutics disclosed completed induction period data from its Phase 2a clinical trial of OD-001 at the United European Gastroenterology Week. The analysis, which included 56 efficacy-evaluable patients, demonstrated that the oral, selective RIPK2 scaffolding inhibitor significantly reduced disease activity in moderate-to-severe ulcerative colitis. The 20 mg twice-daily dose achieved a mean 2.4-point reduction in the modified Mayo score, meeting the trial primary endpoint with statistical significance. Beyond clinical remission, the study showed that symptomatic improvements began as early as the second week of treatment and continued to deepen throughout the 12-week induction phase without reaching a plateau.
Significance
The data strengthens the clinical proof of concept for RIPK2 scaffolding inhibition as a novel therapeutic pathway. Researchers noted a high correlation between clinical outcomes and changes in key inflammatory biomarkers, including fecal calprotectin and hsCRP. Furthermore, transcriptomic findings aligned with clinical activity, providing biological evidence that OD-001 successfully modulates the intended disease pathology. These results establish 20 mg BID as the projected lowest maximally efficacious dose for future trials. The oral administration and favorable safety profile position OD-001 as a potential monotherapy or a backbone for combination regimens in the complex inflammatory bowel disease treatment landscape.
Business and Financial Context
- Maintained a robust cash position of 433.1 million USD as of June 30, 2026, providing an operational runway into the second half of 2028
- Completed a successful initial public offering and concurrent private placement in May 2026, raising approximately 304 million USD
- Advanced the pipeline beyond OD-001 with a planned Clinical Trial Application for the oral SLC15A4 inhibitor OD-002 expected by late 2026
- Operates as a clinical-stage biopharmaceutical entity with zero product revenue, consistent with typical biotechnology development cycles
- Secured a 213 million USD Series D financing round in late 2025 prior to its NASDAQ debut to accelerate precision medicine development
Up 7.0% since our story on 20 Oct: $18.10 when we broke it → $19.36 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $18.10 |
|---|---|
| 20 Oct | $18.99 |
| 21 Oct | $19.00 |
| 22 Oct | $19.08 |
| 23 Oct | $19.60 |
| 26 Oct | $19.30 |
| 27 Oct | $19.50 |
| 28 Oct | $19.54 |
| 29 Oct | $19.83 |
| 30 Oct | $19.54 |
| 2 Nov | $19.53 |
| 3 Nov | $21.57 |
| 4 Nov | $19.50 |
| 5 Nov | $18.88 |
| 6 Nov | $19.23 |
| 9 Nov | $19.15 |
| 10 Nov | $20.00 |
| 11 Nov | $20.99 |
| 12 Nov | $20.10 |
| 13 Nov | $19.14 |
| 16 Nov | $19.36 |
Management Perspective
“Transcriptomic findings that align with clinical activity and are consistent with RIPK2 scaffolding inhibition reinforce the mechanistic rationale for this approach in inflammatory bowel disease, strengthen our confidence in the treatment activity of OD-001, and support its continued clinical development.”
Industry Landscape
The ulcerative colitis market is characterized by a significant unmet need for effective oral therapies that can provide long-term remission for patients who fail standard biologics. Odyssey Therapeutics enters this competitive sector by targeting the RIPK2 pathway, distinct from existing JAK inhibitors and TNF-alpha blockers. This precision approach aims to modulate systemic and intestinal inflammation with fewer off-target effects. Current market dynamics favor the development of oral monotherapies that offer rapid symptomatic relief, a key metric Odyssey met with its 21 percent symptomatic remission rate at Week 2. The company continues to evaluate OD-001 in combination with vedolizumab to expand its potential utility.
| Date | Announcement | Amount |
|---|---|---|
| 12 Oct 2026 | Announced presentation of Phase 2a trial design evaluating OD-001 in combination with vedolizumab at ACG 2026Source: globenewswire.com | – |
| 06 Oct 2026 | Announced oral presentation of additional Phase 2a induction data for OD-001 at UEG Week 2026Source: globenewswire.com | – |
| 04 Aug 2026 | Reported second quarter 2026 financial results and provided pipeline corporate updateSource: SEC filing | – |
| 17 Jun 2026 | Reported first quarter 2026 financial results and positive Phase 2a proof of concept for OD-001Source: SEC filing | – |
| 07 May 2026 | Announced pricing of upsized initial public offering and concurrent private placementSource: cooley.com | $304.0 Million |
| 10 Sep 2025 | Announced closing of oversubscribed Series D financing roundSource: wsgr.com | $213.0 Million |
Management commentary
“These new analyses provide compelling evidence of pharmacologic activity at 20 mg BID, including clinical efficacy in patients with severe endoscopic disease and improvements across markers of intestinal and systemic inflammation.”
| Share price | $18.10 |
|---|---|
| Market cap | $870M |
| Revenue (annual) | $3M |
| 1-month price change | -22.05% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Odyssey Therapeutics, Inc. announcing Phase 2a induction results for OD-001 in ulcerative colitis.
Track Odyssey Therapeutics, Inc. live
Get the next Odyssey Therapeutics, Inc. SEC filing seconds after it lands.